在 1833 例患有各种类型癌症的患者中存在血清 RalA 和血清 p53 自身抗体。
Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers.
机构信息
Department of Surgery, School of Medicine, Toho University, Tokyo, 143-8541, Japan.
Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, 260-8717, Japan.
出版信息
Int J Clin Oncol. 2022 Jan;27(1):72-76. doi: 10.1007/s10147-021-02045-0. Epub 2021 Oct 11.
BACKGROUND
RalA is a member of the Ras superfamily of small GTPases. The Anti-RalA autoantibodies (s-RalA-Abs) act as tumor markers in various types of cancer and are negatively associated with the p53 autoantibodies (s-p53-Abs). This study aimed to evaluate the relationship between s-RalA-Abs and s-p53-Abs in various types of cancer.
METHODS
A total of 1833 cancer patients (esophageal cancer, 172; hepatocellular carcinoma, 91; lung cancer, 269; gastric cancer, 317; colon cancer, 262; breast cancer, 364; and prostate cancer, 358) and 73 healthy subjects were enrolled in the study. The levels of s-RalA-Abs and s-p53-Abs were analyzed using enzyme-linked immunosorbent assay, and the positivity rates and relations between the two autoantibodies were evaluated. The cutoff values for s-RalA abs and s-p53 abs were set as mean + 2 standard deviation and the values higher than the cutoff values were defined as positive.
RESULTS
The titers in all cancer types were significantly higher than those in the controls (P < 0.01). The positivity rates for s-RalA-Abs ranged between 11.7 and 21.5%, and those for s-p53-Abs ranged between 12 and 28.5%. A combined assay of the two antibodies revealed positivity rates of 20.9 and 44.2%. In Stage 0/I/II tumors, the positivity rates of the combination of the two antibodies ranged between 21.5 and 42.3%. The two autoantibodies were complementary to each other in the prostate and breast cancers, but independent in other carcinomas.
CONCLUSION
The combined use of s-RalA-Abs and s-p53-Abs tended to increase the positivity rate in all cancers, including Stage 0/I/II cancers.
背景
RalA 是 Ras 超家族的小 GTP 酶成员。抗 RalA 自身抗体（s-RalA-Abs）在各种类型的癌症中作为肿瘤标志物，与 p53 自身抗体（s-p53-Abs）呈负相关。本研究旨在评估各种类型癌症中 s-RalA-Abs 和 s-p53-Abs 之间的关系。
方法
共纳入 1833 例癌症患者（食管癌 172 例，肝细胞癌 91 例，肺癌 269 例，胃癌 317 例，结肠癌 262 例，乳腺癌 364 例，前列腺癌 358 例）和 73 例健康对照者。采用酶联免疫吸附试验检测 s-RalA-Abs 和 s-p53-Abs 水平，评估两种自身抗体的阳性率及其相关性。将 s-RalA abs 和 s-p53 abs 的截断值设定为平均值+2 个标准差，高于截断值的定义为阳性。
结果
所有癌症类型的滴度均明显高于对照组（P<0.01）。s-RalA-Abs 的阳性率为 11.7%21.5%，s-p53-Abs 的阳性率为 12%28.5%。两种抗体联合检测的阳性率为 20.9%和 44.2%。在 0/Ⅰ/Ⅱ期肿瘤中，两种抗体联合检测的阳性率为 21.5%~42.3%。两种自身抗体在前列腺癌和乳腺癌中相互补充，但在其他癌中则相互独立。
结论
s-RalA-Abs 和 s-p53-Abs 的联合使用倾向于提高所有癌症（包括 0/Ⅰ/Ⅱ期癌症）的阳性率。
Zotero 插件